Neumora Therapeutics(US:NMRA) Globenewswire·2026-01-05 11:35Core Insights - Neumora Therapeutics is positioned for significant value creation with multiple clinical data readouts expected in 2026, including consolidated topline readouts for KOASTAL-2 and KOASTAL-3 in Q2 2026 [1][3] - The company plans to initiate the NMRA-215 clinical program in 2026, following promising preclinical data related to obesity treatment [1][4] - NMRA-511 has shown positive results in a Phase 1b study for Alzheimer's disease agitation, indicating a clinically meaningful effect [1][6] - Neumora's financial position is strong, with cash and equivalents expected to support operations into Q3 2027 [1][7] Pipeline Updates - The KOASTAL studies for navacaprant will see increased enrollment, targeting up to 25% beyond the original 332 participants, with a joint topline data readout expected in Q2 2026 [3] - NMRA-215 is set to enter Phase 1 clinical trials for obesity treatment in the first half of 2026, with weight loss data anticipated by the end of 2026 [4] - The M4 Positive Allosteric Modulator (PAM) franchise is progressing with Phase 1 studies for NMRA-898 and NMRA-861, with a comprehensive update expected in mid-2026 [5] Business Strategy - Neumora aims to redefine neuroscience drug development by focusing on novel therapies for underserved brain diseases, supported by a robust pipeline of seven programs targeting various neuropsychiatric and neurodegenerative disorders [8]